Table 2 |
|||||||||
|
Nasal Symptom Scale scores and sneeze counts during late response phase |
|||||||||
|
Comparison |
Measure |
Hours after Nasal Allergen Challenge |
Treatment |
Mean |
N |
SD |
t |
P (1-tailed) |
|
|
|
|||||||||
|
Loratadine- Placebo |
Nasal Symptoms Score |
2 |
Loratadine |
5.1 |
18 |
3.5 |
-1.10 |
0.143 |
|
|
Placebo |
5.9 |
18 |
3.1 |
||||||
|
4 |
Loratadine |
4.1 |
18 |
3.4 |
-1.43 |
0.086 |
# |
||
|
Placebo |
5.1 |
18 |
3.1 |
||||||
|
6 |
Loratadine |
3.2 |
18 |
2.8 |
-2.57 |
0.010 |
** |
||
|
Placebo |
4.4 |
18 |
3.6 |
||||||
|
8 |
Loratadine |
3.1 |
18 |
2.6 |
-1.05 |
0.153 |
|||
|
Placebo |
3.8 |
18 |
3.4 |
||||||
|
AUC |
Loratadine |
15.5 |
18 |
10.7 |
-1.82 |
0.044 |
* |
||
|
Placebo |
19.3 |
18 |
12.6 |
||||||
|
Sneeze count |
2 |
Loratadine |
2.2 |
17 |
3.0 |
-1.25 |
0.114 |
||
|
Placebo |
3.8 |
17 |
5.5 |
||||||
|
4 |
Loratadine |
2.6 |
17 |
4.0 |
-0.52 |
0.306 |
|||
|
Placebo |
3.2 |
17 |
4.5 |
||||||
|
6 |
Loratadine |
1.4 |
17 |
2.3 |
-2.22 |
0.021 |
* |
||
|
Placebo |
3.6 |
17 |
5.8 |
||||||
|
8 |
Loratadine |
1.2 |
17 |
1.6 |
-1.89 |
0.038 |
* |
||
|
Placebo |
2.7 |
17 |
3.8 |
||||||
|
AUC |
Loratadine |
7.5 |
17 |
7.8 |
-1.79 |
0.047 |
* |
||
|
Placebo |
13.2 |
17 |
17.7 |
||||||
|
Placebo-CBP |
Nasal Symptoms Score |
2 |
Placebo |
5.8 |
17 |
3.1 |
1.39 |
0.091 |
# |
|
CBP |
4.7 |
17 |
2.3 |
||||||
|
4 |
Placebo |
4.9 |
17 |
3.1 |
1.71 |
0.053 |
# |
||
|
CBP |
3.6 |
17 |
2.3 |
||||||
|
6 |
Placebo |
4.2 |
17 |
3.5 |
2.74 |
0.007 |
** |
||
|
CBP |
2.4 |
17 |
2.4 |
||||||
|
8 |
Placebo |
3.5 |
17 |
3.3 |
0.90 |
0.190 |
|||
|
CBP |
2.8 |
17 |
2.6 |
||||||
|
AUC |
Placebo |
18.4 |
17 |
12.4 |
1.86 |
0.041 |
* |
||
|
CBP |
13.6 |
17 |
8.0 |
||||||
|
Sneeze count |
2 |
Placebo |
3.2 |
17 |
5.2 |
1.57 |
0.068 |
# |
|
|
CBP |
1.2 |
17 |
1.6 |
||||||
|
4 |
Placebo |
2.7 |
17 |
4.4 |
1.72 |
0.052 |
# |
||
|
CBP |
1.2 |
17 |
1.9 |
||||||
|
6 |
Placebo |
3.4 |
17 |
5.8 |
1.93 |
0.036 |
* |
||
|
CBP |
0.7 |
17 |
1.0 |
||||||
|
8 |
Placebo |
2.3 |
17 |
3.7 |
0.90 |
0.191 |
|||
|
CBP |
1.5 |
17 |
2.3 |
||||||
|
AUC |
Placebo |
11.5 |
17 |
17.2 |
1.76 |
0.049 |
* |
||
|
CBP |
4.6 |
17 |
3.9 |
||||||
|
Loratadine- CBP |
Nasal Symptoms Score |
2 |
Loratadine |
4.8 |
17 |
3.4 |
0.14 |
0.447 |
|
|
CBP |
4.7 |
17 |
2.3 |
||||||
|
4 |
Loratadine |
3.9 |
17 |
3.4 |
0.28 |
0.393 |
|||
|
CBP |
3.6 |
17 |
2.3 |
||||||
|
6 |
Loratadine |
3.1 |
17 |
2.8 |
1.43 |
0.086 |
# |
||
|
CBP |
2.4 |
17 |
2.4 |
||||||
|
8 |
Loratadine |
2.9 |
17 |
2.6 |
0.20 |
0.421 |
|||
|
CBP |
2.8 |
17 |
2.6 |
||||||
|
AUC |
Loratadine |
14.7 |
17 |
10.5 |
0.51 |
0.308 |
|||
|
CBP |
13.6 |
17 |
8.0 |
||||||
|
Sneeze count |
2 |
Loratadine |
1.8 |
16 |
2.6 |
0.88 |
0.197 |
||
|
CBP |
1.3 |
16 |
1.6 |
||||||
|
4 |
Loratadine |
2.4 |
16 |
4.0 |
1.09 |
0.145 |
|||
|
CBP |
1.3 |
16 |
1.9 |
||||||
|
6 |
Loratadine |
1.3 |
16 |
2.4 |
1.07 |
0.151 |
|||
|
CBP |
0.7 |
16 |
1.0 |
||||||
|
8 |
Loratadine |
1.1 |
16 |
1.5 |
-0.55 |
0.295 |
|||
|
CBP |
1.4 |
16 |
2.3 |
||||||
|
AUC |
Loratadine |
6.6 |
16 |
7.1 |
1.18 |
0.128 |
|||
|
CBP |
4.7 |
16 |
4.1 |
||||||
|
|
|||||||||
|
# P < 0.10, * P < 0.05, ** P ≤ 0.01 |
|||||||||
|
Corren et al. Nutrition Journal 2008 7:20 doi:10.1186/1475-2891-7-20 |
|||||||||
